Anti-TRF2 Monoclonal Antibody

Overview

This product is an anti-TERF2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone AFOB-20; isotype Rabbit IgG; reactivity: Human. Reported application contexts include WB, IHC, ICC, IF (as provided in the source record). Boster Bio Anti-TRF2 Monoclonal Antibody catalog # M00650. Tested in WB, IHC, ICC/IF applications. This antibody reacts with Human.

Key elements and design rationale

• Target: TERF2 (DNA-dependent protein kinase catalytic subunit).
• Antibody format: Monoclonal; clone AFOB-20; isotype Rabbit IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

TERF2 (protein: T-cell surface glycoprotein CD4) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break (DSB) repair and V (D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V (D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D. Contributes to the determination of the circadian period length by antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1 protein stability, most likely through an in machanism. Interacts with CRY1 and CRY2; negatively regulates CRY1 phosphorylation. . Reported cellular localization context: Nucleus. Nucleus, nucleolus. Tissue expression notes (as provided): Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.

Research relevance and current trends

• Research context keywords from the source record include: 2339,DNA/RNA,DNA Damage & Repair,DNA Damage Response,Epigenetics and Nuclear Signaling.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.

Workflow ideas (metafield): Validate TERF2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect TERF2 expression by Western blot in cell or tissue lysates, Detect TERF2 in FFPE tissue sections by immunohistochemistry, Localize TERF2 by immunofluorescence/immunocytochemistry in cultured cells

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 42 kDa; calculated MW: 469089 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 42 kDa
• Cellular localization (provided): Nucleus. Nucleus, nucleolus.
• Tissue details (provided): Found in plasma and platelets and in endothelial, hepatoma and fibrosarcoma cells.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.